Estrogen Receptor Mutations in HR+ Advanced Breast Cancer: Next-Generation Practice Recommendations on Mutation Screening to Guide Therapeutic Decisions

Deepen your understanding of estrogen receptor 1 (ESR1) mutations in HR+ advanced breast cancer by exploring best practices on advanced breast cancer mutation screening. Download summary slides with key data from the live symposium, listen to the expert’s podcast, and rewatch the live event with an on-demand webcast.

Share

Program Content

Events

Activities

Integrating Oral SERDs: HR+/HER2- BC
Integrating Oral SERDs Into Treatment for Patients With HR-positive/HER2-negative Metastatic Breast Cancer and Current Rationale or Medical Need
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2024

Expires: November 12, 2025

Sequencing Oral SERDs: HR+/HER2- BC
Sequencing Novel SERDs in the Treatment of Patients With HR+/HER2- Metastatic Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 15, 2024

Expires: November 14, 2025

Managing Oral SERD Related AEs in HR+/HER2- MBC
Managing AEs With Oral SERDs for Patients With HR+/HER2- Metastatic Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 15, 2024

Expires: November 14, 2025

Faculty

cover img faculity

Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

cover img faculity

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Lilly

AstraZeneca

Lilly